Overall, we have seen an increase in the use of dabigatran after the availability of idarucizumab. We should recognize, however, that we know that all 4 DOACs (direct oral anticoagulants) are ...

The market for oral anticoagulants has advanced significantly since warfarin was essentially the lone option. Still, in some cases, the use of improved direct oral anticoagulants (DOACs) can provoke ...

During the COVID-19 pandemic, one of the most intractable public health challenges was overcoming distrust in government and public health agencies, including among Black and brown communities. Yet in ...

NEW ORLEANS — A reversal agent for the P2Y 12 inhibitor antiplatelet drug ticagrelor (Brilinta/Brilique, AstraZeneca) may soon be available after results of a new study showed immediate and sustained ...

ORLANDO, Fla. (Reuters) - A drug developed by Portola Pharmaceuticals to rapidly reverse the effect of new blood thinning agents in cases of major bleeding or other emergencies proved highly effective ...

TORONTO, ON — A real-world clinical test of idarucizumab (Boehringer Ingelheim) shows the agent safely and effectively reverses the anticoagulant effect of the direct oral thrombin inhibitor ...

After more than 60 years of having only warfarin as an option for oral anticoagulation, several target-specific oral anticoagulants have entered the market. These agents include a direct thrombin ...

Andexanet alfa, a novel reversal agent, was effective at stopping acute major bleeding in patients taking Factor Xa inhibitors, according to results from the ANNEXA-4 study. Stuart J. Connolly, MD, ...

NEW ORLEANS, LA—A novel, specific reversal agent for ticagrelor called PB2452 (PhaseBio) provides immediate and sustained reversal of the antiplatelet effects of the P2Y12 inhibitor as measured by ...

Working in health care I have seen first-hand the devastation the opioid epidemic is having on our communities. Opioids are highly addictive — a fact that the illicit drug market is using to its ...